Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Harm Reduct J. 2012 Jan 1;9(1):1. doi: 10.1186/1477-7517-9-1.

    Prescribing cannabis for harm reduction.

    Source

    PainExhibit,com, 9008 El Cajon Way, #4, Sacramento, CA, 95826, USA. Mark@PainExhibit.com.

    Abstract

    Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.

    PMID:
    22208773
    [PubMed]
    PMCID:
    PMC3295721
    Free PMC Article

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk